As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Transcript (slightly modified)
How does oncology benefit from improving patient access to clinical trials?
How does oncology benefit more from the technology innovations of now and in the future than perhaps other therapeutic areas? I think it’s several things. First, what we are seeing in oncology is more and more deep diagnostic testing, such as next-generation sequencing testing. The more that we have details of the patient and specific requirements for each protocol, such as a specific biomarker and finding that out in the patient’s biomarker testing and those 2 things can be linked up—that’s going to be specific to disease areas like oncology and rare disease. So, I think that’s one place where trials have been particularly tough. It’s sort of this rare patient finding, the needle-in-the-haystack problem, that is pretty unique to oncology.
Another place that is particularly hard about oncology is that the standard of care is changing very, very fast, and so clinical trials that have control arms that reflect standard of care from yesteryear, that’s not going to work for us in oncology. I can’t afford to take care of my patient and my patient can’t afford for me to take care of him or her using old fashioned treatments. So, being able to design clinical trials in oncology that either use data and data informed standard of care so that it’s as contemporary as possible and perhaps doesn’t even need to expose this particular patient to that kind of standard of care, but rather just only the novel treatments are the kinds of things they need in oncology.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More